NDLI: Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. 'the MASTER randomized, controlled trial'.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Mikada, Atsushi Narita, Takuma Yokoyama, Hiroki Yamashita, Risa Horikawa, Yohei Tsukiyama, Katsushi Yamada, Yuichiro
Spatial Coverage	Japan
Description	Country affiliation: Japan Author Affiliation: Mikada A ( Akita University Graduate School of Medicine, Department of Endocrinology, Diabetes and Geriatric Medicine, Akita, Japan); Narita T ( Akita University Graduate School of Medicine, Department of Endocrinology, Diabetes and Geriatric Medicine, Akita, Japan. Electronic address: narita@med.akita-u.ac.jp.); Yokoyama H ( Jiyugaoka Medical Clinic, Internal Medicine, Obihiro, Japan.); Yamashita R ( Jiyugaoka Medical Clinic, Internal Medicine, Obihiro, Japan.); Horikawa Y ( Hiraka General Hospital, Gastroenterology and Diabetes Unit, Yokote, Japan.); Tsukiyama K ( Hiraka General Hospital, Gastroenterology and Diabetes Unit, Yokote, Japan); Yamada Y ( Akita University Graduate School of Medicine, Department of Endocrinology, Diabetes and Geriatric Medicine, Akita, Japan.)
Abstract	AIM: To assess changes in circulating incretin levels and body fat compositions with initial combination therapy with -glucosidase inhibitor and dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes (T2D). METHODS: In this multicenter open-label 24-week trial, Japanese over-weight (BMI ≥ 25 kg/m(2)) patients with T2D not taking medication or taking metformin and/or sulfonylurea were randomly assigned to receive either 50mg of miglitol three times a day (M, n=14), 50mg of sitagliptin once a day (S, n=14), or a combination of both (M+S, n=13). Changes in plasma incretin levels during a meal tolerance test (MTT) and body fat composition with impedance method were evaluated. RESULTS: During MTT, postprandial plasma glucose levels decreased more after M+S than after M or S, and postprandial serum insulin levels decreased significantly after M and M+S whereas they increased after S. After M, active gastric inhibitory polypeptide (aGIP) decreased significantly at 30 min despite a significant increase at 120 min. After S, aGIP levels increased significantly throughout the MTT. After M+S, aGIP increased significantly at 0 and 120 min despite of significant decrease at 30 min. M+S further enhanced postprandial active glucagon-like peptide-1 levels during MTT than S did. Total body fat mass decreased significantly after M and M+S. Visceral fat mass decreased significantly only after M+S. Serum adiponectin increased significantly only after M+S. CONCLUSIONS: In over-weight patients with T2D, M+S may have a beneficial effect on adiposity with relation to these different effects on two incretins.
File Format	HTM / HTML
ISSN	01688227
Issue Number	3
Volume Number	106
e-ISSN	18728227
Journal	Diabetes Research and Clinical Practice
Language	English
Publisher	Elsevier
Publisher Date	2014-12-01
Publisher Place	Ireland
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Therapy Intra-abdominal Fat Research Support, Non-u.s. Gov't Humans Middle Aged Male Epidemiology Blood Journal Article Overweight Hypoglycemic Agents Time Factors Triazoles Dose-response Relationship, Drug Postprandial Period Female Diabetes Mellitus, Type 2 Sitagliptin Phosphate Drug Therapy, Combination Drug Administration Schedule Complications Japan 1-deoxynojirimycin Treatment Outcome Administration & Dosage Metabolism Randomized Controlled Trial Drug Effects Incretins Pyrazines Discipline Endocrinology Follow-up Studies Multicenter Study Analogs & Derivatives
Content Type	Text
Resource Type	Article
Subject	Endocrinology, Diabetes and Metabolism Internal Medicine Endocrinology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Individualised incretin-based treatment for type 2 diabetes.

Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial.

Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.

Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.

Sitagliptin and metformin--novel combination therapy.

Effect of initial combination therapy with sitagliptin and metformin on ß-cell function in patients with type 2 diabetes.

Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.

Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus.

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.

Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. 'the MASTER randomized, controlled trial'.

Similar Documents

Individualised incretin-based treatment for type 2 diabetes.

Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial.

Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.

Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.

Sitagliptin and metformin--novel combination therapy.

Effect of initial combination therapy with sitagliptin and metformin on ß-cell function in patients with type 2 diabetes.

Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.

Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus.

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.

Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. 'the MASTER randomized, controlled trial'.